COSCIENS Biopharma IncNASDAQ:CSCIView on Canadian Exchange
- LAST PRICE2.9900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1700/ 1
- Ask / Lots4.6000/ 1
- Open / Previous Close--- / 2.9900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSCI |
|---|---|---|
| 09:35 ET | 495 | 2.82 |
| 09:46 ET | 945 | 2.8 |
| 09:50 ET | 100 | 2.8 |
| 09:57 ET | 1455 | 2.8 |
| 10:09 ET | 700 | 2.8358 |
| 10:15 ET | 526 | 2.76 |
| 10:22 ET | 100 | 2.75 |
| 10:54 ET | 100 | 2.75 |
| 10:56 ET | 100 | 2.62 |
| 10:58 ET | 300 | 2.76 |
| 11:39 ET | 1100 | 2.76 |
| 11:52 ET | 500 | 2.7582 |
| 12:10 ET | 1000 | 2.8 |
| 12:26 ET | 100 | 2.7 |
| 12:32 ET | 100 | 2.7001 |
| 12:42 ET | 450 | 2.76 |
| 12:48 ET | 1165 | 2.7201 |
| 12:50 ET | 200 | 2.91 |
| 01:36 ET | 1000 | 2.8039 |
| 01:38 ET | 1000 | 2.8722 |
| 02:03 ET | 250 | 2.88 |
| 02:45 ET | 1000 | 2.8756 |
| 02:54 ET | 100 | 2.7665 |
| 02:57 ET | 1000 | 2.835 |
| 03:14 ET | 200 | 2.85 |
| 03:46 ET | 2223 | 2.94 |
| 03:51 ET | 109 | 2.99 |
Nov 12, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
COSCIENS Biopharma Inc | 15.0M | -0.4x | --- |
Plus Therapeutics Inc | 7.1M | -0.5x | --- |
Stemtech Corp | 6.8M | -1.0x | --- |
Palatin Technologies Inc | 18.3M | -0.5x | --- |
InMed Pharmaceuticals Inc | 3.3M | -0.1x | --- |
Evogene Ltd | 8.1M | -0.4x | --- |
Company Information
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Contact Information
- Headquarters
- C/O Norton Rose Fulbright Canada Llp 222 Bay Street, Suite 3000,TORONTO, ON, Canada M5K 1E7
- Phone
- 418-652-8525
- Fax
- 418-948-9191
Executives
- Chairman of the Board
- Ronald Miller
- President, Chief Executive Officer, Director
- Gilles Gagnon
- Chief Financial Officer, Senior Vice President, Director
- Giuliano La Fratta
- Director
- Genevieve Foster
- Director
- Ulrich Kosciessa
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.7M |
|---|---|
Revenue (TTM) | $6.4M |
Shares Outstanding | 3.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-7.79 |
Book Value | $14.99 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -286.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
